May
2024

Co-Dx®

Instructions for Use
Co-Dx™ Logix Smart® Influenza A, Influenza B, and SARS-CoV-2 (ABC) Kit

For *in vitro* diagnostic use

REF **ABC-K-001**

CE

IVD

Co-Dx™ Logix Smart® Influenza A, Influenza B, SARS-CoV-2 (ABC) Kit
CO-DIAGNOSTICS, INC.

CO-DIAGNOSTICS, INC. | 2401 Foothill Dr., Ste D, Salt Lake City, UT 84109 USA

Table of Contents

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

1 INTENDED USE

The **Co-Dx™ Logix Smart® Influenza A, Influenza B, SARS-CoV-2 (ABC)** kit is intended for the qualitative, simultaneous detection and differentiation of nucleic acids from Influenza A, Influenza B, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It targets conserved regions of the virus genomes in lower respiratory tract samples (e.g., bronchoalveolar lavage, sputum, tracheal aspirate), upper respiratory tract samples (e.g., nasopharyngeal, oropharyngeal swabs), and saliva from individuals suspected of having Influenza A, Influenza B, or coronavirus disease 2019 (COVID-19) and its related conditions during the acute phase of the infection.

Positive results are indicative of the presence of Influenza A, Influenza B, and/or SARS-CoV-2 genomic material; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection nor co-infection with other viruses. The agent detected may not be the definite cause of disease. Many laboratories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude Influenza A, Influenza B, and/or SARS-CoV-2 infections and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The **Co-Dx Logix Smart ABC** kit is intended for use by qualified and trained clinical laboratory personnel who are specifically instructed and trained in the techniques of real-time polymerase chain reaction (PCR) and *in vitro* diagnostic procedures.

2 PRODUCT DESCRIPTION AND TEST PRINCIPLE

The **Co-Dx Logix Smart ABC** kit is a real-time, reverse transcription, polymerase chain reaction (rRT-PCR), multiplex test utilizing the Company's patented Co-Primer® technology (Satterfield, 2014) (Poritz & Ririe, 2014). The Co-Primer sets to detect Influenza A (gene [M] Matrix), Influenza B (gene Nonstructural [NS]), and SARS-CoV-2 (gene RNA-dependent, RNA polymerase [RdRp] and E-gene) in lower respiratory tract samples (e.g., bronchoalveolar lavage, sputum, tracheal aspirate), upper respiratory tract samples (e.g., nasopharyngeal swabs, oropharyngeal swabs), and saliva from patients who are suspected of having contracted Influenza A, Influenza B, or coronavirus disease 2019 (COVID-19).

Each **Co-Dx Logix Smart ABC** kit consists of the following components:

- Ready-to-use master mix (MM), complete with an internal Positive Control (IPC) (Human ribonuclease P [RNaseP]) to verify sample and extraction quality

- PC, to verify the performance of the MM and stability of components

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

- Negative control (NC), to verify the MM is free of contamination

2.1 Principles of Operation

The test begins with the selection of the sample type, followed by a collection of the sample by a trained healthcare provider. The sample must be identified following the laboratory quality system and current regulation. The sample must be stored properly until testing in the same facility or shipping to the assigned laboratory.

The **Co-Dx Logix Smart ABC** kit assay is a multiplexed single-step real-time reverse transcription PCR test that can be broken down into the following three stages:

- Sample preparation
- Reverse transcription
- PCR with real-time monitoring

The assay also includes an IPC that acts as an extraction control to confirm the performance of the extraction.

The sample preparation for PCR requires the samples to be processed to break apart cells and viruses so the genetic material is exposed. For this process, a commercially available extraction system is used. The nucleic acids are isolated and purified from the lower respiratory tract fluids (e.g., bronchoalveolar lavage, sputum, tracheal aspirate), upper respiratory tract fluids (e.g., nasopharyngeal and oropharyngeal swabs), or saliva.

The purified nucleic acid is then plated with the **Co-Dx Logix Smart ABC** MM, 10 µl of each. The MM is pre-mixed and contains the necessary components to perform both reverse transcription and PCR and does not need to be prepared ahead of time by the user.

The plated reactions will then be put in the thermocycler using the following cycling conditions and in the following order:

- 15 min at 45°C
- 2 min at 95°C
- 45 cycles x [3s at 95°C, 32s at 55°C]

The first step (15-min at 45°C) is the reverse transcription step where the cDNA is created from the RNA template. The second step (2 min at 95°C) is performed to inactivate the reverse transcriptase and acts as the initial denaturation step for PCR, which is then followed by the thermocycling for PCR.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

During PCR, the labeled forward Co-Primer acts as both the forward primer and probe. During the annealing/extension phase of the PCR, the 5' nuclease activity of Taq polymerase degrades the Co-Primer portion that annealed to the targeted sequence, causing spatial separation between the fluorophore and the quencher which then generates a fluorescent signal.

With each cycle, additional fluorophore molecules are cleaved from their respective probes, increasing the fluorescence intensity. Fluorescence intensity is monitored at the end of each cycle by the real-time thermocycler, specifically the Co-Dx Box.

See Table 1 for the components included in the **Co-Dx Logix Smart ABC** kit.

Table 1

*Components Included in the **Co-Dx Logix Smart ABC Kit***

Cap Color	Component	Symbol	Description	Individual Catalog Number
Brown	**Co-Dx Logix Smart ABC** Master Mix	MM	Proprietary blend of Co-Primer and PCR reagents	TUBE-ABC-0001 (for 1x1000 µL [100 reactions])
Clear	**Co-Dx Logix Smart ABC** Negative Control	NC	Nuclease-free water	TUBE-ABC-0002 (for 1x1000 µL [100 reactions])
Red	**Co-Dx Logix Smart ABC** Positive Control	PC	Proprietary blend of Influenza A/B, SARS-CoV-2 synthetic templates	TUBE-ABC-0003 (for 1x1000 µL [100 reactions])

The kit product code is ABC-K-001 Contact the Co-Diagnostics' Sales department at (801) 438-1036 Ext. 1 or go to www.co-dx.com/contact/ to order.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

3 REAGENT STORAGE AND HANDLING

The following list includes information for reagent storage and handling:

- If one or more of the components are not frozen upon receipt or are compromised during shipment, contact your distributor for assistance. The **Co-Dx Logix Smart ABC** kit is shipped on dry ice. The components of the kit should arrive frozen.
- Store all components immediately at a temperature between -40 °C and -16°C to prevent degradation of reagents.
- Always work with each **Co-Dx Logix Smart ABC** component on ice. Make aliquots, if necessary, to avoid multiple freeze/thaw cycles.
- If you work in an area prone to power outages, keep a back-up generator for your freezer as well as a temperature data log to ensure that the **Co-Dx Logix Smart ABC** kit remains frozen at a temperature from between -40°C and -16°C.
- Use the most up-to-date version of this Instructions for Use document found at Product Information - Co-Dx. Stability data for the product is currently being collected and results will be published and available.

4 MATERIAL REQUIRED BUT NOT INCLUDED WITH THE TEST

The extraction system required but not included with the test is displayed in Table 2. Thermocyclers validated but not included with the test are displayed in Table 3.

Table 2

Extraction and Automation Systems Validated with the Test

Extraction Reagent		Automation Platform (If applicable)	Manufacturer	Sample Input Volume/Sample Elution Volume
Name	Cat. Number			
QIAamp Viral RNA Mini Kit (Qiagen)	52904 (for 50 extractions) 52906 (for 250 extractions)	N/A	Qiagen	200 µL/60 µL

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 3

Thermocyclers Validated but Not Included with the Test

Thermocycler Machine	Catalog Number	Manufacturer
Co-Dx Box	MIC-4	Co-Diagnostics, Inc.
Mic qPCR Cycler	MIC-4	BMS, Bio Molecular Systems
PCRmax Eco 48 Real-Time qPCR System	EW-93947-00	PCRmax Limited
CFX 96 Touch Real-Time PCR Detection System	1855195	Bio-Rad

4.1 Consumables Required but Not Provided

Consumables required but not provided include the following:

- Disposable powder-free gloves and lab coats
- Disposable pipette tips with filters
- A 10% bleach or other appropriate cleaning solution that degrades nucleic acids
- PCR plates or strip tubes for the thermocycler being used

4.2 Equipment Required but Not Provided

Equipment required but not provided include the following:

- Several micropipettes capable of pipetting volumes from 5 µL to 1000 µL
- A cold block or ice
- A vortex and centrifuge
- A Class II Biosafety cabinet, ideally in a Biosafety Level 2 (BSL-2) containment facility, for the extraction
- A PCR workstation, for MM plating and setup
- An appropriate thermocycler

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

5 WARNINGS AND PRECAUTIONS

WARNING!

Before performing any testing or running any patient sample, verify that all instruments have been properly installed, calibrated, and are well maintained. Do **not** use instruments with an outdated calibration.

As with any diagnostic or laboratory experiment, good laboratory practices for molecular biology are essential to the proper performance of the Quantitative Real-Time PCR (qPCR) or any laboratory experiment. Attention should be taken to the procedures particular to the molecular diagnostics procedures. Due to the high sensitivity of **Co-Dx Logix Smart ABC** kit and the qPCR technology, care should be taken while handling samples, handling materials, and performing the assay, to keep reagents and amplification mixtures free of contamination.

Users should do the following:

- Use sterile pipette tips with filters.
- Use standard precautions when handling any patient samples, as they may contain infectious agents.
- Store and extract positive materials (specimens, PCs, and amplicons) separately from other reagents.
- Always use the NC, provided with this kit.
- Consult appropriate Safety Data Sheets (SDS) for safety. The SDS for the **Co-Dx Logix Smart ABC** kit is provided with the shipment. If not provided with the shipment, the SDS can be retrieved from Co-Diagnostics website at the following address: Product Information - Co-Dx.
- To prevent contamination, always use Good Laboratory Practices for Molecular Biology, which requires implementing a unidirectional workflow and the separating negative and positive materials.
- Always use the most recent version of this document. More information that includes the latest study results can be downloaded for free at Product Information - Co-Dx.

6 SAMPLE COLLECTION, HANDLING, TRANSPORT, AND STORAGE

The sample selection, collection, storage, and handling play an essential part in the performance of nucleic acid assays. If the laboratory does not have internal procedures for selection, collection, storage, and handling of the patient specimen, this section provides some basic guidelines; however, laboratories should follow local regulations, internal

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

validation and procedures for sample selection, collection, transport, and storage, and any other handling procedure.

For more information, visit the US Centers for Disease Control (CDC), European CDC and the World Health Organization (WHO) websites at the following addresses:

- CDC - https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html
- European CDC - https://www.ecdc.europa.eu/en/novel-coronavirus/laboratory-support
- WHO - https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance

6.1 Sample Collection

6.1.1 Lower Respiratory Tract Specimen

6.1.1.1 **Bronchoalveolar lavage, or tracheal aspirate**: Collect 2-3 mL of sample into a sterile, leak-proof, screw-cap sputum collection cup or sterile dry container. Refrigerate specimen at a temperature between 2°C and 8°C and ship overnight to the testing laboratory on an ice pack.

6.1.1.2 **Sputum**: Instruct the patient to rinse their mouth with water and have them expectorate deep cough sputum directly into a sterile, leak-proof, screwcap, sputum collection cup or sterile dry container. Refrigerate the specimen at a temperature between 2°C and 8°C and ship overnight to the testing laboratory on an ice pack.

6.1.2 Upper Respiratory Tract Specimen

6.1.2.1 **Nasopharyngeal and oropharyngeal swabs**: Use only synthetic fiber swabs with plastic shafts, and place swabs immediately into sterile tubes containing viral transport media. (Do not use calcium alginate swabs or swabs with wooden shafts, as they may contain substances that inactivate some viruses and inhibit PCR testing.)

6.1.2.2 Keep nasopharyngeal and oropharyngeal specimens in separate vials. Refrigerate specimen at a temperature between 2°C and 8°C and ship overnight to the testing laboratory on an ice pack.

6.1.2.3 For nasopharyngeal swabs, do the following: Insert a swab into the nostril parallel to the palate. Leave the swab in place for a few seconds to absorb secretions, and swab both nasopharyngeal areas with the same swab.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

6.1.2.4 For oropharyngeal swabs (e.g., throat swabs) do the following: Swab the posterior pharynx, avoiding the tongue.

6.1.2.5 **Nasopharyngeal wash/aspirate or nasal aspirate:** Collect 2-3 mL of the sample into a sterile, leak-proof, screwcap, sputum-collection cup, or sterile dry container. Refrigerate specimen at a temperature between 2°C and 8°C and ship overnight to the testing laboratory on an ice pack or collect the sample on a vial with virus transport media which does not require refrigeration or cold chain transport but may require validation by the laboratory.

6.1.3 Saliva

6.1.3.1 Collect 2-3 mL of saliva into a sterile, leak-proof, screw-cap container, or collect saliva up to the fill line for screw-cap saliva collection kits. Refrigerate the specimen at a temperature between 2°C and 8°C and ship overnight to the testing laboratory on ice pack. For saliva collection kits, follow the manufacturer's instructions for storage and shipping conditions (CDC, 2020).

6.2 Sample Handling

6.2.1 Laboratory workers should wear appropriate personal protective equipment (PPE), which includes disposable gloves, laboratory coat/gown, and eye protection when handling potentially infectious specimens. Clinical specimens from patients suspected or confirmed to be infected with influenza A, influenza B, and/or SARS-CoV-2 should be conducted under a certified Class II biosafety cabinet in a BSL-2 containment facility. More details are provided in the *Biosafety in Microbiological and Biomedical Laboratories (BMBL)* (CDC, 2009) or the *WHO Laboratory Biosafety Manual* (WHO, 2004).

6.2.2 For specific instructions on the handling of clinical specimens for coronavirus disease 2019, see also the CDC's webpage for the *Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019* (COVID-19) (CDC, 2020).

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

6.3 Sample Shipping

Specimens known to be, or suspected of containing Influenza A, Influenza B, and/or SARS-CoV-2 that require shipment by air, should be shipped on dry ice as a Biological Substance Category B, UN3373. International regulations, as described in the WHO *Guidance on Regulations for the Transport of Infectious Substances 2015-2016,* should be followed (CDC, 2020). If ground transportation is required, the specimen should be shipped frozen overnight with enough ice to keep it frozen throughout transit. After the collection of the sample and transfer to the clinical lab, the sample will receive an entry into the laboratory system.

6.4 Sample Storage

6.4.1 Process all specimen types within 48 hours after collection.

6.4.2 If storage is needed after 48 hours, store samples frozen, preferably at -70°C (ECDC, 2020).

6.4.3 Avoid repeated freezing and thawing of a specimen.

6.4.4 If a specimen is kept for retesting, aliquot it in different tubes to avoid freezing and thawing cycles.

6.4.5 Regularly monitor and record the temperature in the storage areas to identify potential fluctuations. Domestic refrigerators/freezers with wide temperature fluctuations are not suitable for the storage of frozen specimens (CDC, 2020).

7 PROCEDURE

The WHO recommends recording the full name, date of birth, contact information, and the time and date of collection of the patient sample. Additionally, the following information could also be collected:

- Symptoms, date of onset, duration of symptoms, contact with known COVID-19 cases (e.g., sister, mother).
- Comprehensive travel history (i.e., dates, place, duration of visit).

7.1 Sample Preparation

The quality of the RNA from the extraction of the sample is essential to the performance of **Co-Dx Logix Smart ABC** kit. Perform the extraction protocol by following the manufacturer's instructions.

7.1.1 Extraction of RNA with QIAamp® Viral RNA Mini kit, cat. no. 52904/52906, Qiagen

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

7.1.1.1 Follow the manufacturer's instructions for extraction by using 140 µL of the sample, and an elution using 60 µL of Buffer AVE.

7.1.1.2 For additional sensitivity, load up to 200 µL of patient sample, and increase the volume of Buffer AVL from 560 µL to 800 µL.

7.1.1.3 To ensure the removal of residual wash buffer from the sample prior to elution, perform an additional centrifugation step using a new collection tube (see extraction procedure).

Warning!

Wash buffers used in the extraction kit contain ethanol. It is important to eliminate any traces of ethanol before elution of the nucleic acid. Ethanol is a strong inhibitor of real-time PCR.

7.2 Co-Dx Logix Smart ABC Reagent Setup

Perform these steps to set up the reagent:

7.2.1 Clean all working surfaces with a fresh 10% bleach solution followed by a molecular-grade alcohol or another equivalent method of cleaning that disinfects and degrades nucleic acids.

7.2.2 Vortex all **Co-Dx Logix Smart ABC** MM, PC, and the negative control (NC), and all sample tubes for ~3 seconds.

7.2.3 Briefly spin the MM, PC, NC down before using to ensure reagents are properly mixed and to ensure removal of any condensation or residue from the lids.

7.2.4 Thaw all reagents and samples on ice, or a cold block, before starting the setup.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

7.3 Set Up the Reaction

Perform the steps below to set up the reaction.

7.3.1 Collect enough reaction wells for each of the following:

- One for each NC,
- One for each sample you want to test, and
- One (or more) for each PC

Note: The example below displays the minimum number of wells needed for 5 samples.

PC	1
NC	1
Samples	5
Total wells required	**7**

7.3.2 Pipet 10 µL of MM into each well collected.

7.3.3 Pipet 10 µL of the NC into the appropriate wells (in addition to the 10 µL of MM already in the well).

Note: Ensure that at least one NC is included in each run and that enough space remains for at least one PC.

Important:

- Pipette on ice, if possible.
- Perform PC pipetting and sample setup in a separate area, or at a separate time from the MM and NC.
- Change pipette tips between samples and change pipette tips after pipetting each component.
- Pipet the PC last, if possible, to avoid contamination events.

7.3.4 Pipet 10 µL of sample or PC into the appropriate well.

7.3.5 Seal the reaction plate with an optical adhesive film or seal each reaction tube with its appropriate lid.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

7.3.6 Place the plate or tubes into the rRT-PCR instrument in the correct orientation and start the run.

7.4 Thermocycler Setup

7.4.1 qPCR Instrument Setup for the Co-Dx Box

7.4.1.1 Contact the Laboratory (801) 438-1036 ext. 3 or at www.co-dx.com/contact/ for the template file for download for use with the Co-Dx Box. The template file comes pre-programmed with the PCR instrument setup described below.

7.4.2 qPCR Instrument Setup

7.4.2.1 Define the settings displayed in Table 4.

Table 4

qPCR Instrument Settings

Item	Setting
Reaction Volume	20 µL
Ramp Rate	Default
Passive Reference	None

7.4.3 Program PCR instrument according to the cycling conditions in Table 5.

Table 5

PCR Instrument Cycling Conditions

Stage	Cycles	Temperature	Time
Reverse Transcription	1	45˚C	15 minutes
Initial Denaturation	1	95˚C	2 minutes
Amplification	45	95˚C	3 seconds
		55˚C	32 seconds

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

7.4.4 Define the fluorescence detectors (dyes) as displayed in Table 6.

Table 6

Fluorescence Detectors (Dyes) Definitions

Intended Target	Detector Name	Reporter	Quencher
FLU A specific RNA	FLU A	Quasar® 670	BHQ® - 2
FLU B specific RNA	FLU B	CAL Fluor® Orange 560	BHQ - 2
SARS-CoV-2 specific RNA	SARS-CoV-2	FAM™	BHQ - 1
RNaseP specific DNA (IPC)	RNaseP	CAL Fluor Red 610	BHQ - 2

7.4.5 When the run is finished, ensure that the run file is saved.

8 DATA ANALYSIS

The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

Verification and validation studies performed for **Co-Dx Logix Smart ABC** kit (Catalog number ABC-K-001) were conducted following Good Laboratory Practices for Molecular Biology assays (Viana & Wallis, 2011). If these conditions are not met, the performance will show higher variability due to user errors while experimenting.

8.1 Analysis Settings

8.1.1 Set the analysis parameters on the Co-Dx Box or Mic qPCR Cycler to the following parameters.

8.1.2 Verify after every run that the green channel (monitoring for SARS-CoV-2 RNA), red channel (monitoring for Influenza A RNA), yellow channel (monitoring for Influenza B RNA), and orange channel (monitoring for RNaseP [IPC]) match the following settings:

- Check the box to “Auto Set Threshold”
- “Method” should be set to Dynamic
- “Threshold Level” should be set to 0.100.
- “Threshold Start” should be set to 1.00
- “Ignore Cycles Before” should be set to 5.
- “Exclusion” should be set to Extensive

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

- "Fluorescence Cutoff Level" should be set to 5.0%
- "Initial Y-Axis Scale" should be set to Linear
- Check the box to "Auto Generate Analysis"

8.1.3 For other thermocyclers, follow the manufacturer's instructions for setting an appropriate threshold.

8.2 Positive Controls (PCs)

8.2.1 Highlight the PC reaction well.

8.2.2 Ensure that each PC displays an amplification curve for the SARS-CoV-2 marker in the FAM channel, Influenza A marker in the Quasar 670 (Q670), Influenza B marker in the CF560 channel, and amplification of the internal PC for RNaseP (IPC) in the CF610 channel.

8.2.3 Ensure that the positive amplification curve looks like the purple curve in Figure 1 and has a Cq value below 40 cycles.

Figure 1

*Positive Control (PC) and Negative Control (NC) Signals for **Co-Dx Logix Smart ABC***



2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

8.3 Negative Controls (NCs)

8.3.1 Highlight the NC.

8.3.2 Ensure the results of the NC show no amplification, specifically with a Cq value less than 40. An example of no amplification can be seen in Figure 1, as the red line, which is below the threshold area. The threshold area is the grey band with the red line.

8.4 The Validity of the Diagnostic Test Runs

8.4.1 Ensure that both the PC and NC have passed.

8.4.2 Ensure the control conditions displayed in Table 7 are met.

Table 7

Control Conditions

Control Type	Control Name	Purpose of Control	FLU A	FLU B	SARS-CoV-2	Internal Control (RNaseP)
Positive Control (PC)	FLU A (Quasar®670)	Verifies the performance of the master mix	+	+	+	+
	FLU B (CF®560)					
	SARS-CoV-2 (FAM™)					
	RNaseP (CF®610)					
Negative Control (NC)	Nuclease-free water	Verifies the reagents are free of contamination	-	-	-	-

8.4.3 If controls pass, interpret the sample results.

8.4.4 If any of the controls fail, the run is invalid. Document the run and initiate troubleshooting.

8.4.5 If IPC (RNaseP) fails investigate to eliminate possible splashing, pipetting error, or any other laboratory error.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

8.5 Interpretation of Results

8.5.1 Once the controls have passed, interpret the unknown samples based on three possible outcomes:

- Positive
- Negative
- Invalid

A positive result will show an amplification curve or cycle threshold value for Influenza A (FLU A), Influenza B (FLU B), or SARS-CoV-2 at or below 40 cycles. Amplification curves greater than 40 cycles for the targets are in the uncertainty zone. The presence of a curve, with a Cq at or below 40 cycles, for a sample for FLU A, FLU B, and/or COVID-19, indicates a positive result. The amplification of the RNaseP (IPC) shows that the extraction was successful.

A negative result will show no amplification for FLU A, FLU B, and/or SARS-CoV-2; occasionally amplification greater than 40 cycles may occur in any of the channels. Any amplification curves greater than 40 cycles are in the uncertainty zone and possibly below the limit of detection (LoD). Performing an additional run of the same sample or another sample of the patient in the same or following days should be considered. The absence of a curve for FLU A, FLU B, and/or SARS-CoV-2 indicates a negative result ONLY when the IPC (RNaseP) marker is positive.

An invalid result refers to situations when any of the controls fail. See troubleshooting.

The interpretation of results with Cq values can be translated to Table 8.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 8

*Interpretation of Results for the **Co-Dx Logix Smart ABC***

	SARS-CoV-2	Influenza A	Influenza B	Patient Internal Positive Control (RNaseP)	Positive Control (PC)	Negative Control (NC)	Result
Instrument Reading		+	+	+	+	-	ABC +
	-	-	-	+	+	-	ABC -
	+	-	-	+	+	-	SARS-CoV-2 + FLU A - FLU B -
	-	+	-	+	+	-	SARS-CoV-2 - FLU A + FLU B -
	-	-	+	+	+	-	SARS-CoV-2 - FLU A - FLU B +
	+	+	-	+	+	-	SARS-CoV-2 + FLU A + FLU B -
	-	+	+	+	+	-	SARS-CoV-2 - FLU A + FLU B +
	+	-	+	+	+	-	SARS-CoV-2 + FLU A - FLU B +
	Any Result (+/-)			-	+	-	INVALID See Troubleshooting
				+	-	-	
				+	+	+	

Anything before 40 cycles is considered a positive reading (+). Anything at or after 40 cycles is considered a negative reading (-).

When possible, check that the medical history and/or symptoms match with the result prior to treatment.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

9 TROUBLESHOOTING

Co-Diagnostics Inc. values customer feedback and wants to be informed of any issues with the **Co-Dx Logix Smart ABC** kit**,** even if the recommended steps for troubleshooting solves the issue. To give feedback please fill out the Customer Feedback Form by visiting Customer Feedback - Co-Dx (codiagnostics.com).

9.1 Stability

Real-time and in-use stability studies are currently under testing. Currently, the expiration date of this product has been established as 12 months.

Always use the most recent version of this document for updates as more stability information will be added when studies are completed.

9.2 User Errors

PCR assay is a technique that uses temperature cycling, and a deoxyribonucleic acid (DNA) polymerase to amplify a single or a few copies of a segment of DNA or RNA. Good Laboratory Practices for Molecular Biology Diagnostics (Viana & Wallis, 2011) are necessary for the use of this product. This product is not intended to be used by untrained personnel.

The user needs to have some molecular biology experience and be familiar with the proper pipetting technique to prevent errors, such as splashes, crossover contamination, and errors on volume selection. Pipette tips must be replaced after every pipetting. Gloves must be replaced often. Equipment must have calibration up to date for the pipettes and thermocyclers, when applicable.

A 90-minute online training for Good Laboratory Practices for Molecular Genetics Testing (CDC, 2017) is available at the CDC website at the following link https://www.cdc.gov/labtraining/training-courses/good-lab-practices-molecular-genetics-testing.html

9.3 Invalid Results

9.3.1 **Co-Dx Logix Smart ABC** PC not Amplifying

No amplification from the PC could be the result of one or multiple factors, such as the following:

- Pipetting errors (pipetting control into the wrong well, missing a well, pipetting inadequate amount of reagent)
- Incorrect placement of plates or tubes into the real-time PCR instrument

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

- **Co-Dx Logix Smart ABC** MM or PC degradation (a result of reagents being at temperatures above -16°C for an extended period)
- Use of expired reagents, or the wrong reagents being used

9.3.1.1 If this occurs, consider the run invalid and re-test by re-amplification.

9.3.1.2 If the PC fails a second time, investigate to identify possible causes for error and depending on the investigation results and risks identified in the process, you may need to re-extract the patient samples.

9.3.1.3 If failure of the PC happens a third time after re-extraction and re-amplification, open a new **Co-Dx Logix Smart ABC** PC or MM, and retest.

9.3.1.4 If still failing, please contact Co-Diagnostics Inc. Technical Support by calling (801) 438-1036 ext. 2 or emailing support@co-dx.com.

9.3.2 IPC (RNaseP) not Amplifying in Patient Samples

No amplification from the RNaseP channel could be the result of one or more of the following factors:

- Not enough nuclear material in the patient sample
- PCR inhibitors such as ethanol and heparin
- The extraction was performed incorrectly
- The extraction kit used is not compatible or has a step that eliminates RNaseP DNA.

Note: Positive amplification in any of the target channels indicates a positive result despite the lack of concurrent amplification in the IPC channel. The IPC amplification is dependent on the presence of human genomic DNA (gDNA) in the extraction sample, the amount of which is governed by the type of the patient sample and the extraction procedure used. Samples obtained from culture or sterile/pure sites (e.g., CSF, urine, cell lysates) may not contain the human RNaseP gene. .

9.3.2.1 Investigate if IPC (CF610 channel) shows a negative result while the target channel(s) shows positive result.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

In the investigation the two possible scenarios should be evaluated, including the following:

- The positive result for FLU A, FLU B, and/or SARS-CoV-2 channel(s) is a true positive (TP) while the IPC is negative due to the lack of human RNaseP gene in the sample (absence of human cells in the sample).
- The amplification of FLU A, FLU B, and/or SARS-CoV-2 channel(s) is a false positive (FP) result while the IPC (CF610 channel) is negative due to testing/human errors potentially caused by mix-ups during plating and pipetting, refraction anomalies in the solution or any other cause for FP results.

9.3.3 Failure of any of the controls may indicate that the sample extraction or sample collection have failed. In this scenario, do the following:

9.3.3.1 Perform a new extraction.

9.3.3.2 If the IPC persists to be negative with negative FLU A, FLU B, and SARS-CoV-2 channel, report the result as INVALID with a New Sample Collection Needed request.

9.3.3.3 If the cause for an error is unclear, contact Co-Diagnostics Inc. Technical Support by calling (801) 438-1036 ext. 2 or emailing support@co-dx.com.

9.3.4 Negative Control (NC) Showing Amplification

Amplification of FLU A, FLU B, and/or SARS-CoV-2 in the NC indicates contamination of one or more of the reagents, incorrect placement of plate or tube into the real-time PCR instrument, or pipetting errors. When this occurs, do the following:

9.3.4.1 Interpret the results as invalid and perform a re-test by re-amplification.

9.3.4.2 If the NC fails again, investigate to identify possible causes for error, and depending on the investigation results and risks identified in the process, you may need to re-extract the patient samples.

9.3.4.3 If failure of the NC, after re-extraction and re-amplification, occurs a third time, open a new NC and retest.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

9.3.4.4 If it still fails, interpret the run as invalid and contact Co-Diagnostics Inc. Technical Support by calling (801) 438-1036 ext. 2 or emailing support@co-dx.com.

10 LIMITATIONS

Limitations include the following:

- Strictly comply with the instructions in this document to obtain optimal results.
- Always use the most recent version of this document. This can be downloaded for free at Product Information - Co-Dx.
- Limit the use of this product to personnel who are trained and instructed in real-time PCR techniques and *in vitro* diagnostic device (IVD) procedures.
- Ensure good laboratory practices are used for the proper performance of this assay.
- Upon receipt of reagents, run a test to check the performance of the reagents before testing on patient samples.
- Perform appropriate specimen collection, transport, storage, and processing procedures for optimal results.
- Do not use the **Co-Dx Logix Smart ABC** kit components directly on the specimens collected. Perform an appropriate nucleic acid extraction before using this assay.
- Be aware that the presence of PCR inhibitors may cause false negatives (FN) or invalid results.
- Be aware that potential mutations of the target regions of the SARS-CoV-2 genome covered by this kit may fail to detect the presence of pathogens.
- As with any diagnostic test, interpret results of **Co-Dx Logix Smart ABC** kit with consideration of all clinical and laboratory findings.

11 ANALYTICAL EVALUATION

11.1 Precision

A precision test was performed over 5 days with 2 runs, performed in shifts, a day with 2 machines, and two technicians. Samples were prepared by spiking Influenza A, Influenza B, and/or SARS-CoV-2 Amplirun (Vircell) extracted viral genomic RNA controls into confirmed negative clinical matrix (saliva collected with SDNA-1000 Saliva Collection Device (Spectrum Solutions (Utah, USA), Catalog # SDNA-1000).

The concentrations for the normal and low concentrations are based on the LoD and detection rates of ~99% and 95%, respectively. The difference in the total average Cq and average Cq each day should be less than or equal to 2.0 cycles, with variance lower than 5%, and there should be at least a 95% detection rate for all the markers.

Results have been found with the acceptance criteria with no shift in cycle higher than 2.0 cycles between days, machines, and operators. The detection was within at least 95%, and the coefficient of variance was less than 5%.

See Table 9 for a summary of the combined precision results for **Co-Dx Logix Smart ABC** kit.

Table 9

*Combined Precision Results for the **Co-Dx Logix Smart ABC***

	Cq Average	SD	Call Rate	CV%	Marker Detection Rate (%)
Red Channel					
FLU A [Normal]	34.21	0.61	20/20	1.79	100%
FLU A [Low]	34.99	0.68	20/20	1.95	100%
Combined [Normal]	33.90	0.61	20/20	1.80	100%
Combined [Low]	34.55	0.81	19/20	2.34	95%
Yellow Channel					
FLU B [Normal]	29.76	0.50	20/20	1.67	100%
FLU B [Low]	30.07	0.53	20/20	1.76	100%
Combined [Normal]	29.58	0.50	20/20	1.71	100%
Combined [Low]	29.92	0.55	19/20	1.84	95%
Green Channel					
COVID [Normal]	33.25	0.59	20/20	1.77	100%
COVID [Low]	33.96	0.62	19/20	1.81	95%
Combined [Normal]	33.48	0.46	20/20	1.37	100%
Combined [Low]	33.65	0.49	20/20	1.45	100%

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

11.2 Limit of Detection (LoD) – Analytical Sensitivity

The LoD is the lowest concentration of analyte that is detected at a rate of no less than 95%. The experiment was performed using contrived samples prepared by spiking a reference material in the confirmed negative clinical matrix. To prepare the contrived samples see the following reference material:

- Influenza A: A/New Caledonia/20/1999 (H1N1) strain (BEI Resources, catalog # NR-41799)
- Influenza B Virus: B/Malaysia/2506/2004 strain (BEI Resources, catalog # NR-12280)
- SARS-CoV-2: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, Gamma-Irradiated (BEI Resources, catalog number NR-52287)

The confirmed negative saliva used for the negative matrix was collected with SDNA-1000 Saliva Collection Device (Spectrum Solutions (Utah, USA), Catalog # SDNA-1000). This reference material was spiked in after the lysis step of the QIAamp Viral RNA Mini kit (Qiagen, CAT#52906) manufacturer's extraction protocol, using an input volume of 200 µL and an elution volume of 60 µL.

After the extraction process, the extracts were tested following the **Co-Dx Logix Smart ABC** kit protocol.

A preliminary LoD experiment was performed using different dilutions with the LoD calculated by probit analysis.

Once the LoD range was determined, the LoD concentration was confirmed across different thermocyclers with 20 individual samples replicates. The LoD concentration was confirmed with Co-Dx Box thermocycler (Co-Diagnostics, Inc.) in saliva and sputum (as worst-case for upper and lower respiratory specimen), and confirmed with saliva with CFX96 (Bio-Rad), Eco48 (PCRmax/Cole-Parmer), and Mic qPCR Cycler (Biomolecular Systems).

The detection rate was greater than or equal to 9%% across all thermocyclers at 571.30 $CEID_{50}$/mL or 0.57 $CEID_{50}$/µL for Influenza A, 60.0 $CEID_{50}$/mL or 0.06 $CEID_{50}$/µL for Influenza B, and $1.0x10^3$ copies/mL for SARS-CoV-2.

See Table 10 for the verification of the LoD.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 10

Verification of the LoD

	FLU A (0.57 $CEID_{50}$/µL)	FLU B (0.06 $CEID_{50}$/µL)	SARS-CoV-2 (1.00x10^3 Copies/mL)
Saliva LoD Verification with Co-Dx Box Thermocycler (Co-Diagnostics)			
# Detected	19	20	20
# Samples	20	20	20
Detection Rate (%)	95	100	100
Ct Avg.	35.74	35.21	34.81
Sputum LoD Verification with Co-Dx Box Thermocycler (Co-Diagnostics)			
# Detected	20	19	20
# Samples	20	20	20
Detection Rate (%)	100	95	100
Ct Avg.	36.00	34.76	35.50
Saliva LoD Verification CFX96 (Bio-Rad)			
# Detected	20	20	20
# Samples	20	20	20
Detection Rate (%)	100	100	100
Ct Avg.	38.25	37.41	37.70
Saliva LoD Verification with Eco48 (PCRmax/Cole-Parmer)			
# Detected	19	19	19
# Samples	20	20	20
Detection Rate (%)	95	95	95
Ct Avg.	38.65	38.44	38.19
Saliva LoD Verification Mic qPCR Cycler (Biomolecular Systems)			
# Detected	19	20	20
# Samples	20	20	20
Detection Rate (%)	95	100	100
Ct Avg.	35.88	34.82	36.93

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

11.3 Analytical Specificity – Inclusivity

11.3.1 In-Silico Inclusivity for SARS-CoV-2

An alignment was performed with the oligonucleotide Co-Primer sequences of the COVID-19 Co-Primers with all publicly available nucleic acid sequences for SARS-CoV-2 in GenBank, as well as the GISAID database to demonstrate the predicted inclusivity of the **Co-Dx Logix Smart ABC** kit.

Co-Diagnostics has been performing consistent reviews of the sequence alignment to monitor the sequence conservation. This has been done by analyzing phylogenic mutation genomic data pulled by NextStrain from the GISAID database.

The first alignment was performed on 4-Feb-2020 with posterior queries performed on March, April, May, and June, July, August, September, and October. Partial and cumulative results are displayed. Sequences were obtained from https://nextstrain.org/ncov/gisaid/global.

See Table 11 for the in-silico analysis history.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 11

In-Silico Analysis History

Date of Co-Dx's Analysis for RdRp Marker	SARS-CoV-2 samples analyzed (number of sequences in the analyzed subsample)	Sequences in the pool with 100% homology	Single nucleotide mutation events: Sequences with 1 mismatch on Co-Dx target (98% homology)	Double nucleotide mutation events: Sequences with 2+ mismatches on Co-Dx target (95% homology)	Multiple nucleotide mutation events: Sequences with 3+ mismatches on Co-Dx target <95% homology)
27-Jan-20	14	14 (100%)	0 (0%)	0 (0%)	0 (0%)
4-Feb-20	53	53 (100%)	0 (0%)	0 (0%)	0 (0%)
17-Mar-20	571	570 (99.8%)	1 (0.2%)	0 (0%)	0 (0%)
6-Apr-20	3639	3634 (99.86%)	5 (0.14%)	0 (0%)	0 (0%)
4-May-20	4468	4459 (99.80%)	9 (0.2%)	0 (0%)	0 (0%)
3-Jun-20	4558	4537 (99.54%)	21 (0.46%)	0 (0%)	0 (0%)
6-Jul-20	11361	11328 (99.71%)	33 (0.29%)	0 (0%)	0 (0%)
10-Aug-20	22054	22012 (99.81%)	42 (0.19%)	0 (0%)	0 (0%)
9-Sep-20	4417	4394 (99.48%)	23 (0.52%)	0 (0%)	0 (0%)
12-Oct-20	5139	5114 (99.51%)	25 (0.49%)	0 (0%)	0 (0%)
Date of Co-Dx's Analysis for gene E Marker	**SARS-CoV-2 samples analyzed number of sequences in analyzed subsample**	**Sequences in the pool with 100% homology**	**Single nucleotide mutation events: Sequences with 1 mismatch on Co-Dx target (98% homology)**	**Double nucleotide mutation events: Sequences with 2+ mismatches on Co-Dx target (95% homology)**	**Multiple nucleotide mutation events: Sequences with 3+ mismatches on Co-Dx target <95% homology)**
4-Feb-20	53	53 (100%)	0 (0%)	0 (0%)	0 (0%)
9-Sep-20	4417	4400 (99.62%)	14 (0.32%)	2 (0.05%)	1 (0.2%)
12-Oct-20	5139	5126 (99.96%)	11 (0.21%)	0 (0%)	2 (0.04%)

Each marker in **Co-Dx Logix Smart ABC** kit is expected to detect strains with a single mismatch without difficulty. At 2 mismatches, each marker in **Co-Dx Logix Smart ABC** kit is expected to detect with

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

significant Cq delay. Events of 3+ mismatches are expected to lead to no detection by that marker. To maintain 99%+ expected sensitivity for both markers, 99%+ of the sampled sequences should maintain less than three mismatches on either marker. To maintain 99%+ expected sensitivity for either marker, 99%+ of the sampled sequences should main should maintain <3 mismatches on both markers.

The alignment data and posterior updated analyses have shown less than three mismatches for both the forward and reverse Co-Primers on 100% of sequences for the RdRp marker and 99.96% of sequences for the E-Gene marker in the NextStrain Global Subsampling of the GISAID database. Therefore, there is a ~0.04% prediction of false-negative results for the E-Gene marker alone and no prediction of false-negative results for both markers together based upon the available data.

11.3.2 In-Silico Inclusivity for Influenza A and Influenza B

An alignment was performed with the oligonucleotide Co-Primer sequences of the Influenza A and Influenza B Co-Primer sets with all sequences from the Influenza Research Database (restricted to human hosts) as of 02-Jul-2020 (Influenza A) and 21-Jul-2020 (Influenza B) to demonstrate the predicted inclusivity of the **Co-Dx Logix Smart ABC** kit. See Table 12 for the in-silico analysis history for Influenza A and Influenza B.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 12

In-Silico Analysis History for Influenza A and Influenza B

Date of Co-Dx's Analysis for Influenza A gene M marker	Co-Primer set	Influenza A (number of sequences in analyzed subsample)	Sequences in the pool with 100% homology	Single nucleotide mutation events: Sequences with 1 mismatch on Co-Dx target (98% homology)	Double nucleotide mutation events: Sequences with 2+ mismatches on Co-Dx target (95% homology)	Multiple nucleotide mutation events: Sequences with 3+ mismatches on Co-Dx target <95% homology)
02-Jul-20	Forward	**41,352**	40,851 (98.79%)	488 (1.18%)	13 (0.03%)	0 (0%)
02-Jul-20	Reverse	**41,352**	38,763 (93.74%)	2,449 (5.92%)	133 (0.32%)	7 (0.02%)
Date of Co-Dx's Analysis for Influenza B gene NS marker	**Co-Primer set**	**Influenza B (number of sequences in analyzed subsample)**	**Sequences in the pool with 100% homology**	**Single nucleotide mutation events: Sequences with 1 mismatch on Co-Dx target (98% homology)**	**Double nucleotide mutation events: Sequences with 2+ mismatches on Co-Dx target (95% homology)**	**Multiple nucleotide mutation events: Sequences with 3+ mismatches on Co-Dx target <95% homology)**
21-Jul-20	Forward	**12,385**	11,764 (94.99%)	616 (4.97%)	5 (0.04%)	0 (0%)
21-Jul-20	Reverse	**12,385**	12,155 (98.14%)	224 (1.81%)	6 (0.05%)	0 (0%)

The in-silico analysis predicts that the **Co-Dx Logix Smart ABC's** Influenza A marker will detect >99.66% of the available sequenced Influenza A and Influenza B markers are expected to detect >99.91% of the available sequenced Influenza B. This lower bound was found by adding up the total number of sequences that could have 3+ combined mismatches on the Forward and Reverse by assuming the maximum possible number of mismatches on the opposite Co-Primer. The actual number of combinations will be lower and therefore the percentage of strains expected to be successfully detected is higher than the above-quoted numbers.

11.3.3 Wet-Test Inclusivity for SARS-CoV-2 and Influenza A

Inclusivity wet testing was performed to confirm that the **Co-Dx Logix Smart ABC** kit can detect multiple strains/isolates of the targets. See Table 13 for the results. Testing was performed by spiking negative saliva extract at 9x, 3x, and 1x LoD, run in quadruplicate. Due to the lack of available reference material, Infuenza B inclusivity wet test has not been performed at this moment.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 13

Co-Dx Logix Smart ABC *Inclusivity Testing Results*

SARS-CoV-2					
Strain/Isolate	**Concentration**	**# Detected**	**# Samples**	**Detection Rate (%)**	**Ct avg.**
Spanish Isolate	9x LoD	4	4	100.00	32.84
	3x LoD	4	4	100.00	34.46
	1x LoD	4	4	100.00	37.31
Germany/BavPat1/2020	9x LoD	4	4	100.00	34.98
	3x LoD	4	4	100.00	36.44
	1x LoD	2	4	50.00	35.67
Italy-INMI1	9x LoD	4	4	100.00	32.17
	3x LoD	4	4	100.00	33.62
	1x LoD	4	4	100.00	35.95
Influenza A					
Strain/Isolate	**Concentration**	**# Detected**	**# Samples**	**Detection Rate (%)**	**Ct avg.**
H1 (A/Brisbane/59/2007)	9x LoD	4	4	100.00	35.54
	3x LoD	4	4	100.00	36.06
	1x LoD	2	4	50.00	37.41
H3 (A/Perth/16/2009)	9x LoD	4	4	100.00	33.49
	3x LoD	4	4	100.00	35.08
	1x LoD	3	4	75.00	36.94

11.4 Analytical Specificity, Cross-Reactivity, and Exclusivity

11.4.1 In-Silico Cross Reactivity for SARS-CoV-2

11.4.2 *In-silico* Analysis BLASTn analysis queries of the SARS-CoV-2 Co-Primers were performed against public domain nucleotide sequences. The database search parameters were as follows:

- The nucleotide collection consists of GenBank+EMBL+DDBJ+PDB+RefSeq sequences, but excludes EST, STS, GSS, WGS, TSA, patent sequences as well as phase 0, 1, and 2 HTGS sequences and sequences longer than 100 Mb.
- The database is non-redundant. Identical sequences have been merged into one entry, while preserving the accession, GI, title, and taxonomy information for each entry.
- The database is reviewed consistently to detect potential mutations in the SARS-CoV-2, Influenza A, and Influenza B targeted regions.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

- The search parameters automatically adjust for short input sequences and the expect threshold is 1000.
- The match and mismatch scores are 1 and -3, respectively.
- The penalty to create and extend a gap in an alignment is 5 and 2, respectively.
- BLASTn was run individually for every organism requested listed in Table 14. The list contains microorganisms relevant to the respiratory infections present in oral and samples.

It is expected that the *E* gene marker will efficiently amplify many strains of both Bat SARS-like coronavirus as well as SARS-CoV. It is not expected that the *E* gene marker will cross-amplify with any other coronaviruses, human microflora, or any other organisms that have been sequenced in the National Center for Biotechnology Information (NCBI) database.

Co-Primers have a slightly different cross-reactivity risk profile than traditional primers. Due to the low TMs of the Priming and Capture sequences, Co-Primers are more susceptible to mismatches (Satterfield, 2014). Internal experiments show that a single mismatch on either forward or reverse causes a noticeable delay in amplification, with more mismatches causing significant suppression of signal. Three or more mismatches on the forward and reverse combined are expected to result in no detectable amplification.

The results suggest that the **Co-Dx Logix Smart® ABC** kit does not cross-react to any of the non-target organisms tested in the wet test or *In-Silico* analysis. The negative samples did not show any amplification, therefore, no FPs occurred due to cross-reactivity. Positive samples in the presence of non-target organism genetic material, in most cases, did not reduce the ability of the **Co-Dx Logix Smart® ABC** kit to produce positive results.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 14

Microorganism Included in the Cross-Reactivity In-Silico Assessment

High priority pathogens from the same genetic family	High priority organisms likely in the circulating area	Other microorganisms of importance
Human coronavirus 229E	Adenovirus	Influenza C
Human coronavirus OC43	Human Metapneumovirus (hMPV)	Parechovirus
Human coronavirus HKU1	Parainfluenza virus 1-4	*Corynebacterium diphtheriae*
Human coronavirus NL63	Influenza A & B	*Legionella non-pneumophila*
SARS-coronavirus	Enterovirus	*Bacillus anthracis* (Anthrax)
MERS-coronavirus	Respiratory syncytial virus	*Moraxella catarrhalis*
	Rhinovirus	*Neisseria elongata*
	Chlamydia pneumoniae	*Neisseria meningitides*
	Haemophilus Influenza	Leptospirosis
	Legionella pneumophila	*Chlamydia psittaci*
	Mycobacterium tuberculosis	*Coxiella burnetii* (Q-Fever)
	Streptococcus pneumoniae	*Staphylococcus aureus*
	Streptococcus pyogenes	
	Bordetella pertussis	
	Mycoplasma pneumoniae	
	Pneumocystis jirovecii (PJP)	
	Pooled human nasal wash – to represent diverse microbial flora in the human respiratory tract	
	Candida albicans	
	Pseudomonas aeruginosa	
	Staphylococcus epidermidis	
	Staphylococcus salivarius	

11.4.3 In-Silico Cross Reactivity for Influenza A/B

Significant homology is defined as 3 or fewer mismatches on a single Forward or Reverse Co-Primer.

- Influenza A Forward Co-Primer: No significant homology was found with any non-influenza A organisms.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

- Influenza A Reverse Co-Primer: No significant homology was found with any non-influenza A organisms.
- Influenza B Forward Co-Primer: No significant homology was found with any non-influenza B organisms.
- Influenza B Reverse Co-Primer: No significant homology was found with any non-influenza B organisms.

It is not expected that either the Influenza A or the Influenza B markers will cross-amplify with any other human microflora or any other organisms that have been sequenced in the NCBI database.

11.4.4 Wet-Test Exclusivity

Exclusivity wet testing was performed to confirm that the **Co-Dx Logix Smart ABC** kit does not cross react with non-target organisms. The test was performed by spiking negative sputum or saliva, with non-target organisms, or the non-target organism's extracted genome. The materials that were already extracted were spiked post extraction.

Non-target organisms were spiked in at a final concentration of 1e4 copies/rxn (1e6 copies/mL) and run in duplicate. Additionally, to verify that the presence of non-target genomic DNA/RNA does not affect the ability to detect SARS-CoV-2, non-target organisms were spiked in at a final concentration of 1e4 copies/rxn (1e6 copies/mL) and the AMPLIRUN® RNA Controls for the Influenza A, Influenza B, and SARS-CoV-2 was spiked in at 5x LoD and run in triplicate.

The data generated from the specificity-exclusivity runs are summarized in Table 15. Based on the results, the presence of the non-target organism's genomic material did not significantly affect the amplification of either the *RdRp* target or the *E* gene target ≥ 2 Cq. Additionally, there was no amplification in the reactions that included only the non-target organism, including the SARS-CoV-1 (2003) which has showed some cross-reactivity *In-Silico* analysis.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 15

***Co-Dx Logix Smart ABC** Exclusivity Testing*

	Influenza A	Influenza B	SARS-CoV-2	Negative Sample
Human coronavirus OC43	Positive	Positive	Positive	Negative
Human coronavirus HKU1	Positive	Positive	Positive	Negative
Human coronavirus NL63	Positive	Positive	Positive	Negative
SARS-coronavirus	Positive	Positive	Positive	Negative
MERS-coronavirus	Positive	Positive	Positive	Negative
Human Metapneumovirus (hMPV)	Positive	Positive	Positive	Negative
Parainfluenza virus 3	Positive	Positive	Positive	Negative
Influenza A	Positive	Positive	Positive	Negative
Influenza B	Positive	Positive	Positive	Negative
Enterovirus (e.g., EV68)	Positive	Positive	Positive	Negative
Respiratory syncytial virus	Positive	Positive	Positive	Negative
Rhinovirus	Positive	Positive	Positive	Negative
Chlamydia pneumoniae	Positive	Positive	Positive	Negative
Haemophilus influenzae	Positive	Positive	Positive	Negative
Legionella pneumophila	Positive	Positive	Positive	Negative
Mycobacterium tuberculosis	Positive	Positive	Positive	Negative
Streptococcus pneumoniae	Positive	Positive	Positive	Negative
Streptococcus pyogenes	Positive	Positive	Positive	Negative
Bordetella pertussis	Positive	Positive	Positive	Negative
Mycoplasma pneumoniae	Positive	Positive	Positive	Negative
Pneumocystis jirovecii (PJP)	Positive	Positive	Positive	Negative
Pooled human nasal wash	Positive	Positive	Positive	Negative
Candida albicans	Positive	Positive	Positive	Negative
Pseudomonas aeruginosa	Positive	Positive	Positive	Negative
Staphylococcus epidermidis	Positive	Positive	Positive	Negative
Streptococcus salivarius	Positive	Positive	Positive	Negative

11.5 Clinical Evidence

Clinical evidence was established by a mix of clinical samples with complimentary contrived samples on a total of 90 randomized samples. Of those, 30 were remnant SARS-CoV-2 positive clinical samples, 30 negative clinical samples, 15 contrived Influenza A positive samples, and 15 contrived Influenza B positive samples. The contrived samples were prepared using reference material spiked into confirmed negative clinical matrix.

- Influenza A: A/New Caledonia/20/1999 (H1N1) strain (BEI Resources, catalog # NR-41799).
- Influenza B Virus: B/Malaysia/2506/2004 strain (BEI Resources, catalog # NR-12280).

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

The contrived samples were made at a variety of concentrations from ~3x LoD to ~4000x LoD. All samples were then extracted with the QIAamp Viral RNA Mini kit (Qiagen, catalog number 52904/52906) and tested with the **Co-Dx Logix Smart ABC** kit. For comparator assay, one CE Marking registered/EUA-authorized and another EUA-authorized test were comparators for SARS-CoV-2. For the contrived Influenza samples the comparator was an in-house procedure. There was one discrepant result with an overall agreement of 98.89%. The data is summarized in Table 16.

Table 16

Clinical Study with Results for 90 Randomized Samples

Sample	Results Call	Sample Key	Results Match?	Sample	Results Call	Sample Key	Results Match?
1	Negative	Negative	Yes	46	Negative	Negative	Yes
2	Influenza B	Influenza B	Yes	47	Negative	Negative	Yes
3	Influenza B	Influenza B	Yes	48	Influenza B	Influenza B	Yes
4	SARS-CoV-2	SARS-CoV-2	Yes	49	SARS-CoV-2	SARS-CoV-2	Yes
5	Influenza B	Influenza B	Yes	50	SARS-CoV-2	SARS-CoV-2	Yes
6	Negative	Negative	Yes	51	Influenza A	Influenza A	Yes
7	Negative	Negative	Yes	52	SARS-CoV-2	SARS-CoV-2	Yes
8	SARS-CoV-2	SARS-CoV-2	Yes	53	SARS-CoV-2	SARS-CoV-2	Yes
9	Influenza A	Influenza A	Yes	54	Influenza B	Influenza B	Yes
10	Influenza A	Influenza A	Yes	55	Negative	Negative	Yes
11	SARS-CoV-2	SARS-CoV-2	Yes	56	SARS-CoV-2	SARS-CoV-2	Yes
12	Negative	Negative	Yes	57	Influenza B	Influenza B	Yes
13	Negative	Negative	Yes	58	Influenza A	Influenza A	Yes
14	SARS-CoV-2	SARS-CoV-2	Yes	59	SARS-CoV-2	SARS-CoV-2	Yes
15	Influenza B	Influenza B	Yes	60	SARS-CoV-2	SARS-CoV-2	Yes
16	Negative	Negative	Yes	61	Influenza A	Influenza A	Yes
17	Negative	Negative	Yes	62	SARS-CoV-2	SARS-CoV-2	Yes
18	Negative	Negative	Yes	63	Influenza B	Influenza B	Yes
19	Influenza A	Influenza A	Yes	64	Negative	Influenza A	**No**
20	SARS-CoV-2	SARS-CoV-2	Yes	65	Influenza B	Influenza B	Yes
21	SARS-CoV-2	SARS-CoV-2	Yes	66	SARS-CoV-2	SARS-CoV-2	Yes
22	SARS-CoV-2	SARS-CoV-2	Yes	67	Negative	Negative	Yes
23	Negative	Negative	Yes	68	Negative	Negative	Yes
24	Influenza A	Influenza A	Yes	69	Influenza A	Influenza A	Yes
25	Influenza A	Influenza A	Yes	70	Influenza B	Influenza B	Yes
26	Influenza B	Influenza B	Yes	71	SARS-CoV-2	SARS-CoV-2	Yes
27	Influenza A	Influenza A	Yes	72	Negative	Negative	Yes
28	Influenza B	Influenza B	Yes	73	SARS-CoV-2	SARS-CoV-2	Yes
29	SARS-CoV-2	SARS-CoV-2	Yes	74	Negative	Negative	Yes

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Sample	Results Call	Sample Key	Results Match?	Sample	Results Call	Sample Key	Results Match?
30	SARS-CoV-2	SARS-CoV-2	Yes	75	Negative	Negative	Yes
31	Influenza A	Influenza A	Yes	76	Influenza A	Influenza A	Yes
32	SARS-CoV-2	SARS-CoV-2	Yes	77	SARS-CoV-2	SARS-CoV-2	Yes
33	Negative	Negative	Yes	78	Negative	Negative	Yes
34	Negative	Negative	Yes	79	Negative	Negative	Yes
35	Influenza A	Influenza A	Yes	80	SARS-CoV-2	SARS-CoV-2	Yes
36	SARS-CoV-2	SARS-CoV-2	Yes	81	Negative	Negative	Yes
37	SARS-CoV-2	SARS-CoV-2	Yes	82	SARS-CoV-2	SARS-CoV-2	Yes
38	SARS-CoV-2	SARS-CoV-2	Yes	83	Influenza B	Influenza B	Yes
39	Negative	Negative	Yes	84	Negative	Negative	Yes
40	SARS-CoV-2	SARS-CoV-2	Yes	85	Negative	Negative	Yes
41	Negative	Negative	Yes	86	Negative	SARS-CoV-2	**No**
42	Negative	Negative	Yes	87	Negative	Negative	Yes
43	Influenza B	Influenza B	Yes	88	Negative	Negative	Yes
44	Influenza A	Influenza A	Yes	89	Negative	Negative	Yes
45	SARS-CoV-2	SARS-CoV-2	Yes	90	Influenza B	Influenza B	Yes

11.5.1 Diagnostic Accuracy

The number of TP, FP, TN, and FN were collected and used to calculate the sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), and Matthews correlation coefficient (MCC) were calculated from the totals. See Table 17.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

Table 17

*Diagnostic Accuracy of **Co-Dx Logix Smart ABC** Kit*

Influenza A		Influenza B		SARS-CoV-2	
True Negatives (TN)	30	True Negatives (TN)	30	True Negatives (TN)	30
False Positives (FP)	0	False Positives (FP)	0	False Positives (FP)	0
True Positives (TP)	15	True Positives (TP)	15	True Positives (TP)	30
False Negatives (FN)	1	False Negatives (FN)	0	False Negatives (FN)	1
Sensitivity	96.774	Sensitivity	100	Sensitivity	96.774
Specificity	100	Specificity	100	Specificity	100
Accuracy	0.984	Accuracy	1.000	Accuracy	0.984
PPV	1.000	PPV	1.000	PPV	1.000
NPV	0.968	NPV	1.000	NPV	0.968
MCC	0.953	MCC	1.000	MCC	0.953

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

11.6 Performance Summary

See Table 18 for a performance summary.

Table 18

*Performance Summary for the **Co-Dx Logix Smart ABC***

Co-Dx Logix Smart ABC Performance Characteristics			
Application	**Qualitative Multiplex PCR test, detection for Influenza A, Influenza B, and SARS-CoV-2**		
Limit of Detection	Influenza A	Influenza B	SARS-CoV-2
	571.3 $CEID_{50}$/mL	60.0 $CEID_{50}$/mL	411.2 copies/mL
Sensitivity*	96.78%	100%	96.78%
Specificity*	100%	100%	100%
Sample type	Lower respiratory samples (e.g., bronchoalveolar lavage, sputum, tracheal aspirate), upper respiratory samples (e.g., nasopharyngeal and oropharyngeal swabs), and saliva		
Time to detection	Approximately 90 minutes, depending on the instrument used		
Thermal cycler compatibility	The test should work with the following thermal cyclers: • Co-Dx Box (Co-Diagnostics, Inc.) • Mic cycler (BMS, Biomolecular Systems) • ECO48 (PCR Max) • CFX96 (Bio-Rad) The test should work with most qPCR systems with the following channel compatibilities: • FAM • CF560 (VIC) • CF610 (ROX) • Quasar 670 (Cy5)		
Extraction kit compatibility	QIAamp® Viral RNA Mini kit (Qiagen, CAT#52904, 52906)		

* Sensitivity based on clinical study of 30 clinical remnant positive samples, 15 contrived Influenza A, and 15 contrived Influenza B, and 30 negative clinical samples.

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

12 MANUFACTURER AND AUTHORIZED REPRESENTATIVE

Manufacturer:
Co-Diagnostics, Inc
2401 S Foothill Dr. Ste D
Salt Lake City, UT 84109
Phone: +1 (801) 438-1036
Email: info@co-dx.com
Website: www.co-dx.com

Authorized Representative:
mdi Europa GmbH
Langenhagener Str. 71
D-30855 Hannover-Langenhagen
Germany
Phone: +49 511 39 08 95 30
Email: info@mdi-europa.com
Website: www.mdi-europa.com

13 REFERENCES

CDC. (2009). *Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition.* Retrieved from CDC Laboratories: https://www.cdc.gov/labs/BMBL.html

CDC. (2017, Oct 27). *CDC Laboratory Training: Good Laboratory Practices for Molecular Genetics Testing.* Retrieved Mar 5, 2019, from Centers for Disease Control and Prevention: https://www.cdc.gov/labtraining/training-courses/good-lab-practices-molecular-genetics-testing.html

CDC. (2020, Feb 7). Coronavirus Disease 2019 (COVID-19): Information for Laboratories. Retrieved from Centers for Disease Control and Prevention: https://www.cdc.gov/coronavirus/2019-ncov/downloads/processing-sputum-specimens.pdf

CDC. (2020, Feb 16). Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). Retrieved September 15, 2018, from World Health Organization: https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Flab-biosafety-guidelines.html

ECDC. (2020, Jun 15). *Laboratory support for COVID-19 in the EU/EEA > Testing for SARS-CoV-2 virus*. Retrieved Oct 20, 2020, from European Centre for Disease Prevention and Control: https://www.ecdc.europa.eu/en/novel-coronavirus/laboratory-support

Poritz, M., & Ririe, K. (2014, Mar). Getting things backwards to prevent primer dimers. Journal of Molecular Diagnosis, 159-62. doi:10.1016/j.jmoldx.2014.01.001

Satterfield, B. (2014, Mar). *Cooperative primers: 2.5 million-fold improvement in the reduction of nonspecific amplification. Journal of Molecular Diagnosis*, 163-73. doi:10.1016/j.jmoldx.2013.10.004

Viana, R. V., & Wallis, C. L. (2011). *Good Clinical Laboratory Practices (GLCP) for Molecular Based Tests Used in Diagnostic Laboratories.* In D. I. Akyar, Wide Spectra of Quality Control (pp. 29-52). InTech. Retrieved from http://www.intechopen.com/books/wide-spectra-of-quality-control/goodclinical-laboratory-practice-gclp-for-molecular-based-tests-used-in-diagnostic-laboratories

WHO. (2004). *Laboratory Biosafety Manual. Retrieved from Emergencies preparedness, response:* https://www.who.int/csr/resources/publications/biosafety/WHO_CDS_CSR_LYO_2004_11/en/

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com

14 LEGEND OF PACKAGE SYMBOLS

See Table 19 for a legend of package symbols.

Table 19

Legend of Package Symbols

Icon	Description
IVD	*In vitro* diagnostic medical device
REF	Catalog number
LOT	Batch code
	Use-by-date
	Contains sufficient for x tests/reactions
	Protect from light
	Temperature limit
	Consult Instructions for Use document
	Non-sterile product - Do not sterilize
	Manufacturer
EC REP	Authorized representative in the European Community
CE	CE-Marking for IVD in compliance to EU Directive 98/79/EC

2401 S. Foothill Dr. Ste. D., Salt Lake City, UT 84109, USA • 801.438.1036 • www.co-dx.com